Physician profile
Jonathan David Eisner
NPI 1881686004
$9,518.44
in general payments reported to CMS, 2019-2025
37 companies · $1,877 in 2025
The $1,877 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,552 · 2020: $581 · 2021: $1,466 · 2022: $1,347 · 2023: $1,167 · 2024: $1,530 · 2025: $1,877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,339 · Education: $234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,338.79 |
| Education | $234.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,583.30 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,217.96 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $1,035.43 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $959.38 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Pfizer INC. | $436.52 | 2019-2025 | |
| Celgene Corporation | $392.24 | 2021-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $318.32 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $279.77 | 2024-2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $236.68 | 2019-2025 | Rebyota |
| Merck Sharp & Dohme LLC | $221.03 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $176.03 | 2020-2024 | Linzess |
| Enterra Medical, INC. | $171.68 | 2023-2024 | |
| Ardelyx, INC. | $171.06 | 2023-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $139.15 | 2021-2023 | |
| Grifols USA, LLC | $123.12 | 2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $119.67 | 2021 | |
| Covidien LP | $118.34 | 2019 | |
| Alnylam Pharmaceuticals INC. | $107.29 | 2023-2025 | Givlaari |
| Ge Healthcare | $87.31 | 2025 | |
| Braintree Laboratories, INC. | $85.62 | 2019-2023 | Suflave |
| Phathom Pharmaceuticals, INC. | $69.67 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $61.21 | 2021 | |
| Celltrion USA INC. | $60.50 | 2024 | Zymfentra |
| Evoke Pharma, INC. | $55.95 | 2021-2022 | |
| Romark Laboratories, Lc | $36.23 | 2020 | |
| Fresenius Kabi USA, LLC | $33.37 | 2023-2024 | Idacio |
| Redhill Biopharma INC. | $31.19 | 2023 | Talicia |
| Sandoz INC. | $23.97 | 2024 | Hyrimoz |
| Blueprint Medicines Corporation | $23.97 | 2024 | Ayvakit |
| Daiichi Sankyo INC. | $23.75 | 2020 | |
| Lucid Diagnostics INC. | $20.69 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $19.99 | 2025 | Iqirvo |
| Dova Pharmaceuticals | $17.09 | 2019 | |
| Gilead Sciences, INC. | $16.51 | 2019 | |
| Endo Pharmaceuticals INC. | $15.68 | 2019 | |
| Intra-Sana Laboratories | $14.39 | 2022 | |
| Meridian Bioscience INC. | $14.38 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Eisner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.